These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30857648)

  • 1. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
    Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
    Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
    Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
    Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
    Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
    Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of methotrexate, actinomycin D, and etoposide for treating low-risk gestational trophoblastic neoplasia.
    Baptista AM; Belfort P
    Int J Gynaecol Obstet; 2012 Oct; 119(1):35-8. PubMed ID: 22877838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
    Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
    Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia.
    Turan T; Karacay O; Tulunay G; Boran N; Koc S; Bozok S; Kose MF
    Int J Gynecol Cancer; 2006; 16(3):1432-8. PubMed ID: 16803542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Cost-Effectiveness Between Actinomycin D Versus Methotrexate-Folinic Acid in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Lertkhachonsuk AA; Hanvoravongchai P
    J Reprod Med; 2016; 61(5-6):230-4. PubMed ID: 27424364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
    Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
    Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
    Poli JG; Paiva G; Freitas F; Mora P; Velarde LGC; Junior JA; Filho JR; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2021 Sep; 162(3):638-644. PubMed ID: 34266689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide.
    Kanno T; Matsui H; Akizawa Y; Usui H; Shozu M
    J Gynecol Oncol; 2018 Nov; 29(6):e89. PubMed ID: 30207097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia.
    Sato S; Yamamoto E; Niimi K; Ino K; Nishino K; Suzuki S; Kotani T; Kajiyama H; Kikkawa F
    Int J Clin Oncol; 2020 Jan; 25(1):203-209. PubMed ID: 31520175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia.
    Wang Y; Miao JW; Wang T; Wang Y; Wu YM; Kong WM; Su L; Duan W
    J Chemother; 2016 Apr; 28(2):135-9. PubMed ID: 27105436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Kang HL; Zhao Q; Yang SL; Duan W
    Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
    Rattanaburi A; Boonyapipat S; Supasinth Y
    Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EP-EMA regimen (etoposide and cisplatin with etoposide, methotrexate, and dactinomycin) in a series of 18 women with gestational trophoblastic neoplasia.
    Han SN; Amant F; Leunen K; Devi UK; Neven P; Vergote I
    Int J Gynecol Cancer; 2012 Jun; 22(5):875-80. PubMed ID: 22635033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
    Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
    Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
    Maestá I; Nitecki R; Desmarais CCF; Horowitz NS; Goldstein DP; Elias KM; Berkowitz RS
    Gynecol Oncol; 2020 May; 157(2):372-378. PubMed ID: 32037196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 16-year experience in treating low-risk gestational trophoblastic neoplasia patients with failed primary methotrexate chemotherapy.
    Wu X; Qin J; Shen T; Fei W; Chen L; Xie X; Lu W
    J Gynecol Oncol; 2020 Jul; 31(4):e36. PubMed ID: 32026657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
    Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
    Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.